Urologix to Host Its Fiscal Year 2013 Second Quarter Conference Call Business Wire MINNEAPOLIS -- January 30, 2013 Urologix^®, Inc. (Nasdaq:ULGX) will host a conference call to present fiscal year 2013 second quarter results on Tuesday, February 5, 2013 at 4:00 p.m. CT, following the Company’s post-market press release on the same day. On the day of the call, please dial 1-866-578-5788 and enter the Participant Passcode 18011408 at least 10 minutes prior to the call. The conference call will be broadcast live over the Internet at www.urologix.com. Greg Fluet, Chief Executive Officer, will host the call. Webcast listeners should log on at least 10 minutes prior to the scheduled start time of the call to register and download or install any required audio software. A replay of the call will be available until February 12, 2013 at 4:00 p.m. CT (5:00 p.m. ET). To listen to the replay, please dial 1-888-286-8010 and enter the Participant Passcode 54233981. The webcast is also being distributed over CCBN’s Investor Distribution Network to both institutional and individual investors. Individual investors can listen to the call through CCBN’s individual investor center at www.companyboardroom.com or by visiting any of the investor sites in CCBN’s Individual Investor Network. Institutional investors can access the call via CCBN’s password-protected event management site, StreetEvents (www.streetevents.com). About Urologix Urologix, Inc., based in Minneapolis, develops, manufactures, markets and distributes minimally invasive medical products for the treatment of obstruction and symptoms due to Benign Prostatic Hyperplasia (BPH). Urologix’ Cooled ThermoTherapy™ produces targeted microwave energy combined with a unique cooling mechanism to protect healthy tissue and enhance patient comfort. The Cooled ThermoTherapy™ product line includes the CoolWave® and Targis® Control Units and the CTC Advance® and Targis® catheter families. The Prostiva® RF Therapy System distributed by Urologix delivers radio frequency energy directly into the prostate destroying prostate tissue, reducing constriction of the urethra, and thereby relieving BPH voiding symptoms. Both of these products provide safe, effective and lasting relief of the symptoms and obstruction due to BPH. Prostiva® is a registered trademark of Medtronic, Inc., used under license. All other trademarks are the property of Urologix. Contact: Urologix, Inc. Brian Smrdel, Chief Financial Officer 763-475-1400 email@example.com
Urologix to Host Its Fiscal Year 2013 Second Quarter Conference Call
Press spacebar to pause and continue. Press esc to stop.